

Special Issue

Autonomic Dysfunction in Neurological Disorders: Novel Mechanisms and Targets

Message from the Guest Editors

The dysfunction of the autonomic nervous system is associated with many neurological diseases as a consequence or causality of primary diseases. Studies have been carried out to determine the mechanisms of dysautonomia in neurological disorders such as Alzheimer's disease, Parkinson's disease, depression, and neurogenic hypertension. In addition, dysautonomia also importantly contributes to metabolic diseases, such as diabetes, obesity, and metabolic syndrome, because it may lead to insulin resistance, altered lipid metabolism, and hypertension in metabolic syndrome. However, the role of autonomic dysfunction in creating or maintaining the pathology of neurological diseases is not still completely understood. This Special Issue invites investigators to contribute original research articles and review articles that will help us understand the novel mechanisms of autonomic dysfunction in neurological diseases. Potential topics include, but are not limited to, the following: autonomic dysfunction in neurological disorders; dysautonomia in insulin resistance in metabolic diseases; and dysautonomia in response to external environmental changes.

Guest Editors

Dr. De-Pei Li

Department of Medicine, Center for Precision Medicine, School of Medicine, University of Missouri, Columbia, MO 65212, USA

Prof. Dr. Zixi Cheng

UCF College of Medicine, Orlando, FL, USA

Deadline for manuscript submissions

closed (31 July 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/188658

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).